RxDoctor Payments Data

Victoria Fox

Nurse Practitioner · Fort Wayne, INNPI 1306372560

Payments from drug & device makers

$718in general payments, 2019–2025

Across 27 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$316
  • Sanofi-aventis U.S. LLC$148
  • Johnson & Johnson$39
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$37
  • Novo Nordisk$34
  • AstraZeneca$33
  • plus $112 from 6 others

What the payments were for

  • Food & beverage$718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$718 in reported general payments places this provider in the 65th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$21,988
Medicare patients
88
Services billed
730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$51,026
RybelsusSemaglutide30$46,126
TrulicityDulaglutide25$45,864
MounjaroTirzepatide28$36,999
JardianceEmpagliflozin20$33,597
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$33,577
JanuviaSitagliptin Phosphate26$22,637
EliquisApixaban15$18,223
FarxigaDapagliflozin Propanediol11$13,807
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$5,679
Aripiprazole18$4,504
VascepaIcosapent Ethyl14$3,975
Oxcarbazepine18$3,063
Clozapine16$2,597
Levothyroxine Sodium223$2,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$34$97,15271 claims
Boehringer IngelheimJardiance$15$33,59720 claims
AstraZenecaFarxiga$33$13,80711 claims
AbbVieSynthroid$316$65620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →